TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02949232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Dosing following the tapering scheme of the treatment of the treatment arm
Study: NCT02713737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heated humidified high-flow nasal cannula
Description: HFNC device (Airvo™, Fisher＆Paykel, Auckland, New Zealand) with a heated circuit (Fisher＆Paykel,900PT501) and nasal cannula(optiflow TM,Fisher＆Paykel). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) \> 92%.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: noninvasive ventilation
Description: TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 \> 92%.
Study: NCT01690923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal mask
Description: Nasal mask (Mirage Activa, Micro, FX)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal mask
Description: Nasal mask (Mirage Activa, Micro, FX)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillows mask
Description: Nasal pillows mask (Swift FX)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillows mask
Description: Nasal pillows mask (Swift FX)
Study: NCT02377011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving cognitive behaviour therapy (PS CBT)
Study: NCT00545571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Mircera will be administered intravenously every 4 weeks for a total of 52 weeks. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
Study: NCT03100864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: 12 weeks treatment
Study: NCT02277197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.~Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended.
Study: NCT00639314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pylorus-preserving pancreaticoduodenectomy
Description: pylorus-preserving resection is division of the duodenum 3-4cm distal to the pylorus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pylorus-resecting pancreaticoduodenectomy
Description: In PrPD, the stomach is divided just above the pylorus ring. The nearly total stomach more than 95% was preserved.
Study: NCT02115919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukocyte Interleukin, Injection 200IU
Description: Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukocyte Interleukin, injection 400IU
Description: Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.
Study: NCT02056002

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: - Standard CPAP educational training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer-Buddy System
Description: * Two 30-minute in person sessions with Peer Buddy~* Standard CPAP educational training~* Eight phone conversations with Peer Buddy over 3 months~* Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~- Home visit to collect CPAP information~Three Month Visit:~* Questionnaires~* Psycho Motor Vigilance Test (PVT) Video Game~* Collect CPAP information~* Measure weight~* Measure blood pressure~Six Month Visit:~* Questionnaires~* PVT (Video game)~* Collect CPAP information~* Measure Weight~* Measure Blood Pressure~* Evaluate the program and Peer Buddy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: - Educational Brochures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: - Educational DVD videos mailed to participant
Study: NCT00104637

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sildenafil citrate
Description: sildenafil citrate 25 mg by mouth thrice daily (po tid)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: sildenafil citrate 25 mg by mouth thrice daily (po tid)
Study: NCT01111422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months
Study: NCT00104637

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mg po tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 25 mg po tid
Study: NCT05918393

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: functional communication training
Description: During functional communication training, signaled intervals of reinforcement (i.e., the functional reinforcer is available contingent on communication) and extinction (i.e., the functional reinforcer is unavailable and thus both problem behavior and communication are on extinction) will be alternated within a single session. All communication responses will be reinforced every time they occur during the signaled reinforcement intervals.
Study: NCT03757403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDD1609
Description: RDD1609 to be applied on the perianal area BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDD1609
Description: RDD1609 to be applied on the perianal area BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole 100 MG
Description: Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole 100 MG
Description: Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine)
Study: NCT03571022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: USE-MI System
Description: Pilot Phase: 10 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for 1 month and receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s).~Second Phase: Up to 50 subjects will continue with their ART or PrEP medication and begin using the USE-MI system. Subjects will wear a smartwatch every day to monitor their pill taking activity for up to 6 months. During their first month, subjects will receive weekly phone calls to obtain feedback on the system. During the first call, subjects will respond to 2 questionnaires about how they are taking their daily ART or PrEP pill(s). Subjects will then have monthly follow-up visits to complete a brief questionnaire about how they are taking their daily ART or PrEP pill(s).
Study: NCT01447862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinavess (Vernakalant)
Description: 3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corvert (Ibutilide)
Description: Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.
Study: NCT02980705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG1622 I dose
Description: Injection
Study: NCT00307853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traumeel S
Description: All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traumeel S
Description: All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
Study: NCT03191123

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatic resection
Description: The aim of this intervention is to reach curative resection.
Study: NCT02980705

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dose
Description: Injection
Study: NCT02411708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SANGUINATE
Description: Single two-hour infusion of SANGUINATE

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single two-hour infusion of placebo
Study: NCT03191123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: The aim of this intervention is one of the palliative treatment.
Study: NCT05145608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine ER tablet 50mg
Description: In each study period, a single 50 mg dose of lamotrigine will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine ER tablet 50mg
Description: In each study period, a single 50 mg dose of lamotrigine will be administered orally with about 240 mL of water at ambient temperature, in the morning, while subjects are seated, following a 10-hour overnight fast.
Study: NCT01052623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
Description: 1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
Study: NCT03486964

Intervention type: DRUG
Intervention: DPP-4 inhibitors
Description: Patients will be retrospectively evaluated after the addition of a DPP-4 inhibitor to previously taken anti-diabetic therapy
Study: NCT05540730

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait Analysis
Description: Foot plantar pressure with pedobarography and arm swing with video camera will be analyzed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait Analysis
Description: Foot plantar pressure with pedobarography and arm swing with video camera will be analyzed.
Study: NCT02579317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resonance Breathing
Description: Breathing is paced with a pre-installed iPhone app that includes a visual pacer.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Resonance Breathing
Description: Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
Study: NCT03402672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-administered, e-health application
Description: AWAITS is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT when they were actively using. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention.
Study: NCT01392456

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of two screw type dental implants
Description: Each patient (of the 69 recruited) will receive 2 screw-type Straumann (Institute Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, in a 1-stage non-submerged procedure according to a strict protocol (Weingart D and ten Bruggenkate 2000).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of two screw type dental implants
Description: Each patient (of the 69 recruited) will receive 2 screw-type Straumann (Institute Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, in a 1-stage non-submerged procedure according to a strict protocol (Weingart D and ten Bruggenkate 2000).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of two screw type dental implants
Description: Each patient (of the 69 recruited) will receive 2 screw-type Straumann (Institute Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, in a 1-stage non-submerged procedure according to a strict protocol (Weingart D and ten Bruggenkate 2000).
Study: NCT03023540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PXT3003
Description: Liquid oral solution, twice 5 mL (Dose 1) bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PXT3003
Description: Liquid oral solution, twice 5 mL (Dose 1) bid
Study: NCT02453659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Tolerance Treatment for Weight Concern (DT-W)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HE)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation counseling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine Patch
Study: NCT04656678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance
Description: Focal ultrasound guided cryoablation using uroNav system Version 4.0 and Dyna CAD software version 5.0.
Study: NCT01030471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based cognitive-behavioral treatment
Description: Participants will engage in ten weekly sessions aimed at improving depressive symptoms and medication compliance via reducing family conflict and improving communication among family members.
Study: NCT01544192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gingko Biloba
Description: 2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gingko Biloba
Description: 2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gingko Biloba
Description: 2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gingko Biloba
Description: 2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gingko Biloba
Description: 2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: α-tocopherol
Description: 2x300 mg α-tocopherol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: α-tocopherol
Description: 2x300 mg α-tocopherol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: α-tocopherol
Description: 2x300 mg α-tocopherol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: α-tocopherol
Description: 2x300 mg α-tocopherol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: α-tocopherol
Description: 2x300 mg α-tocopherol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: control group did not receive oral neuroprotective agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: control group did not receive oral neuroprotective agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: control group did not receive oral neuroprotective agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: control group did not receive oral neuroprotective agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: control group did not receive oral neuroprotective agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant formula
Description: 2x1 tablet AOF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant formula
Description: 2x1 tablet AOF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant formula
Description: 2x1 tablet AOF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant formula
Description: 2x1 tablet AOF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant formula
Description: 2x1 tablet AOF
Study: NCT00814541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT02336347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVP-923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVP-923
Study: NCT01463358

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)
Description: pacing in DDD60 is supposed to prevent events of syncope, presyncope of cardioinhibitory origin and symptom associated to av block

Intervention type: DEVICE
Group type: OTHER
Intervention: DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)
Description: pacing in DDDI30 is supposed to act as a safety backup upfront to episodes of syncope, presyncope or AV block, but not supposed to reduce symptoms.
Study: NCT03973697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penn Microbiome Therapy - 001
Description: Fecal Microbiota for Transplant, enema product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penn Microbiome Therapy - 001
Description: Fecal Microbiota for Transplant, enema product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penn Microbiome Therapy - 002
Description: Fecal Microbiota for Transplant, suspension product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penn Microbiome Therapy - 002
Description: Fecal Microbiota for Transplant, suspension product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penn Microbiome Therapy - 003
Description: Fecal Microbiota for Transplant, capsule product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penn Microbiome Therapy - 003
Description: Fecal Microbiota for Transplant, capsule product